PT 141 | 10 MG

PT-141 (also known as Bremelanotide) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH). It functions as a potent melanocortin receptor agonist (primarily targeting MC3R and MC4R in the central nervous system), activating brain pathways involved in sexual arousal, desire, and motivation—distinct from vascular mechanisms of PDE5 inhibitors like sildenafil.

Unlike hormone-based therapies, PT-141 works centrally to enhance sexual desire and arousal without directly altering testosterone, estrogen, or other peripheral hormones, making it a unique tool in sexual wellness research.

Potential human benefits (drawn from clinical trials on Bremelanotide for HSDD in women, early studies in men showing erectile responses, and extensive anecdotal reports in wellness, sexual health, and performance communities):

• Enhanced sexual desire and libido — stimulates central pathways to increase spontaneous thoughts of intimacy, motivation, and "sexual appetite," often described as reduced "low desire" or "food noise" equivalent for sex.
• Improved arousal and sexual response — promotes stronger arousal, heightened sensitivity, and better erectile function in men (including spontaneous or enhanced erections); in women, supports greater physical readiness and satisfaction.
• Better sexual performance and satisfaction — many users report more intense orgasms, prolonged enjoyment, increased frequency of activity, and overall elevated confidence/intimacy experiences.
• Mood and emotional perks — anecdotal accounts frequently highlight uplifted mood, reduced performance anxiety, and a general boost in relational vitality tied to melanocortin activation.
• Broad applicability — effective across genders and in contexts like low libido from stress, age, medications, or hormonal shifts, without relying on vascular blood flow alone.

Human evidence includes FDA-approved use of subcutaneous Bremelanotide (Vyleesi) for hypoactive sexual desire disorder (HSDD) in premenopausal women, with trials showing significant increases in desire, reduced distress, and improved satisfaction scores. Early research in men demonstrated dose-dependent erectile activity and synergy with PDE5 inhibitors; off-label exploration continues for broader sexual dysfunction. Large-scale trials for men or non-FDA indications remain limited, with benefits often self-reported and rapid-onset (effects within minutes to hours).

Typically researched via subcutaneous injection (e.g., 1–2 mg, timed 45–60 minutes before activity) or intranasal forms in some studies, PT-141 stands out in sexual health research for its brain-centered, non-hormonal mechanism—offering targeted support for desire, arousal, performance, and intimacy through natural melanocortin pathways. 

Important Notice:

This product is intended for research use only.
Not for human or animal use of any kind.
Not a drug. Not approved for clinical or therapeutic use.

This product is intended for research use only.
Not for human or animal use of any kind.
Not a drug. Not approved for clinical or therapeutic use.